Crescendo Biologics Limited

United Kingdom · 60 Employees
Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical candidate from Crescendo's T cell enhancing pipeline. Crescendo is also developing CB213, a preclinical PD-1 x LAG-3 multi-specific Humabody. The Company's ability to develop multi-functional Humabody therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human VH domain building blocks (Humabody VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody-based formats can also be applied across a range of non-cancer indications. Beyond Crescendo's proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody), which is expected to enter global Phase 2 clinical development in patients with psoriasis. Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital. For more information, please visit www.crescendobiologics.com.

概述

国家 United Kingdom
成立时间 2009
总部 meditrina babraham research campus #260, babraham, cambridgeshire, united kingdom
电话号码 +44 12 2349 7140
网站 http://www.crescendobiologics.com
LinkedIn http://www.linkedin.com/company/crescendo-biologics-ltd
Twitter https://twitter.com/humabody
Facebook
员工数 60
行业 research,
简介 Crescendo Biologics is focused on novel T cell enhancingtherapeutics in immuno-oncology.

技术

Apache

Load Balancers

Google Maps

Other

Google Maps (Non Paid Users)

Other

Google Tag Manager

Tag Management

Mobile Friendly

Other

Outlook

Email Providers

Shutterstock

Other

Typekit

Fonts

WordPress.org

CMS

YouTube

Online Video Platforms

reCAPTCHA

Captcha

常见问题

Crescendo Biologics Limited 在哪里?

Crescendo Biologics Limited 的总部位于 meditrina babraham research campus #260, babraham, cambridgeshire, united kingdom

Crescendo Biologics Limited 的电话号码是多少?

Crescendo Biologics Limited 的电话号码是 +44 12 2349 7140

Crescendo Biologics Limited 的官方网站是什么?

Crescendo Biologics Limited 的公司官方网站是 http://www.crescendobiologics.com

Crescendo Biologics Limited 是做什么的?

Crescendo Biologics is focused on novel T cell enhancingtherapeutics in immuno-oncology.

Crescendo Biologics Limited 的业务有哪些?

Crescendo Biologics Limited 的年收入是多少?

Crescendo Biologics Limited 的收入是 7857000美元

Crescendo Biologics Limited 有多少员工?

Crescendo Biologics Limited 有 60 名员工

Crescendo Biologics Limited 属于哪个行业?

Crescendo Biologics Limited 从事以下行业: research

Crescendo Biologics Limited 使用什么技术?

Crescendo Biologics Limited 使用的一些流行技术包括: Apache,Google Maps,Google Maps (Non Paid Users),Google Tag Manager,Mobile Friendly,Outlook,Shutterstock,Typekit,WordPress.org,YouTube,reCAPTCHA

如何联系 Crescendo Biologics Limited?

Crescendo Biologics Limited 联系信息: 电话号码:+44 12 2349 7140， 网站:http://www.crescendobiologics.com， 邮箱：aco***@***.com

Crescendo Biologics Limited 的社交媒体链接是什么?

Crescendo Biologics Limited 领英：http://www.linkedin.com/company/crescendo-biologics-ltd,fackbook：,twitte:https://twitter.com/humabody

Crescendo Biologics Limited 是一家上市公司吗?

不是

Crescendo Biologics Limited 的最后一轮融资是什么时候?

Crescendo Biologics Limited在2018-04-30T00:00:00.000+00:00结束了最后一轮融资,金额达70M$。

谁投资 Crescendo Biologics Limited?

Crescendo Biologics Limited 有 6 家投资者,包括 Sofinnova Partners, EMBL Ventures, Takeda Ventures, Inc, Andera Partners, IP Group plc、Astellas Venture Management、EMBL Ventures, Imperial Innovations, Astellas Venture Management, Sofinnova Partners、Imperial Innovations, Astellas Venture Management, Sofinnova Partners、Sofinnova Partners, Rainbow Seed Fund、Avlar BioVentures, Sofinnova Partners, UK Innovation & Science Seed Fund, Aitua Ltd。

管理层

Amelia Copas

Finance Director

Chris Wyre

Senior Scientist II

Colette Johnston

VP Discovery

Davide Girolamo

Senior Scientist I

Lis Mable

Head of Clinical Operations

员工

Isabella Ascanio

Research Scientist

Jude Akinwale

Team Leader, Discovery - Protein Production

Angie Edghill

Office Manager and PA to Dr Pack CEO

Phil Hayes

Molecular Geneticist

Phil Bland-Ward

Chief Development Officer (CDO)

外贸获客 查找关键决策人

10亿+海关交易数据，1.2亿企业数据，2亿+企业联系人数据，1000千万真实采购商。覆盖200+个国家及地区，95%外贸重点拓展市场，可根据行业、经营范围等多方位挖掘目标客户。
免费试用

Top-ranked on G2 Crowd

全球B2B企业库 海关贸易数据 展会采购数据

工作更少，成就更大，销售更聪明

查找更多 B2B 联系人，丰富并验证记录
Email Address

全球B2B企业库

海关贸易数据

展会采购数据

Top-ranked on G2 Crowd

OR
Sign Up with Google